Su1010 Comparison of Efficacy and Safety of Hyoscine Butylbromide Versus Anisodamine for Acute Gastric or Intestinal Spasm-Like Pain: Results From a Randomized, Double-Blind, Parallel-Group, Multi-Center Phase III Trial in Chinese Patients

2016 ◽  
Vol 150 (4) ◽  
pp. S443
Author(s):  
Chunping Zhu ◽  
Fei Jiang ◽  
Xiao-hua Hou ◽  
Rongquan Wang ◽  
Xiaozhong Guo ◽  
...  
Keyword(s):  
Phase Iii ◽  
Chinese Patients ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Phase Iii Trial ◽  
Hyoscine Butylbromide ◽  
Parallel Group

scholarly journals Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: a novel protocol for a double-blind, Phase III trial

2020 ◽  
Vol 15 (1) ◽  
pp. 35-48 ◽  
Author(s):  
Kamal Hamed ◽  
Marc Engelhardt ◽  
Mark E Jones ◽  
Mikael Saulay ◽  
Thomas L Holland ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Treatment Options ◽  
Phase Iii ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Phase Iii Trial ◽  
Common Cause ◽  
Staphylococcus Aureus Bacteremia ◽  
Parallel Group ◽  
Advanced Generation

Although Staphylococcus aureus is a common cause of bacteremia, treatment options are limited. The need for new therapies is particularly urgent for methicillin-resistant S. aureus bacteremia (SAB). Ceftobiprole is an advanced-generation, broad-spectrum cephalosporin with activity against both methicillin-susceptible and -resistant S. aureus. This is a Phase III, randomized, double-blind, active-controlled, parallel-group, multicenter, two-part study to establish the efficacy and safety of ceftobiprole compared with daptomycin in the treatment of SAB, including infective endocarditis. Anticipated enrollment is 390 hospitalized adult patients, aged ≥18 years, with confirmed or suspected complicated SAB. The primary end point is overall success rate. Target completion of the study is in the second half of 2021. Clinicaltrials.gov identifier: NCT03138733

Sign in / Sign up

Export Citation Format

Share Document